We respond to a new report from The Institute of Cancer Research, London, into cancer clinical trials
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
09 Dec 2021
We respond to Macmillan Cancer Support's warning that "almost 50,000 people are still missing a cancer diagnosis in the UK"
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
26 Nov 2021
Responding to new research into the impact of dairy on breast cancer risk
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
17 Nov 2021
We respond to NHS England breast cancer waiting times: September 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
11 Nov 2021
We respond to new guidelines for the treatment of secondary breast cancer agreed at the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6)
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
07 Nov 2021
We respond to new survey results from the ABC6 Conference titled “Advanced breast cancer patients denied opportunities to join clinical trials. Patient advocate calls for collaboration to improve access to trials”
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
04 Nov 2021
We respond to new research titled “Major global study reveals risk of breast cancer spreading to other parts of the body"
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, responded to new research presented at the Advanced Breast Cancer Sixth International Consensus Conference.
03 Nov 2021
We respond to draft NICE decision to not recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today (Tuesday 26 October 2021) announced its provisional decision to not recommend breast cancer treatment tucatinib with trastuzumab and capecitabine for routine use on the NHS in England for treating HER2 positive, locally advanced or secondary breast cancer after at least two prior anti-HER2 treatment regimens.
26 Oct 2021
We respond to Macmillan Cancer Support's warning of 'perfect storm' of Covid and staff shortages
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
22 Oct 2021
We respond to a new study into eating nuts and breast cancer recurrence
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
20 Oct 2021
We respond to a report from the IPPR and CF suggesting it could take over a decade to clear the cancer treatment backlog in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
24 Sept 2021
We respond to new data for Enhertu presented at the European Society for Medical Oncology conference
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
19 Sept 2021